Patent details
LUC00287 Product Name: Asciminib or a pharmaceutically acceptable salt thereof, such as asciminib hydrochloride
Basic Information
- Publication number:
- LUC00287
- Type:
- SPC
- SPC Type:
- Medical
- Basic Patent Number:
- EP137306528
- Legal Status:
- Pending & Published
- Application number:
- LUC00287
- First applicant's nationality:
- Procedural language:
- French
Marketing Authorization
- Marketing Authorization Number:
- EU/1/22/1670
- Marketing Authorization Type:
- Marketing Authorization Date:
- 26/08/2022
- Marketing Authorization Status:
- Accepted
- Marketing Authorization Country:
- Luxembourg (LU)
Dates
- Filing date:
- 02/12/2022
- First Marketing Authorization date:
- 26/08/2022
- Grant date:
- Activation date:
- Publication date:
- 05/12/2022
- Lapsed date:
- Expiration date:
- Renunciation date:
- Revocation date:
- Annulment date:
- Basic SPC Expiration:
- 26/08/2037
- SPC Extension Expiration:
- 26/08/2037
- Rejection date:
- Withdrawal date:
Owner
- From:
- 02/12/2022
- Name:
- Novartis AG
- Address:
- Lichtstrasse 35, 4056 Basel, Switzerland (CH)
Agent
- Name:
- Dennemeyer & Associates S.A.
- From:
- 02/12/2022
- Address:
- 55, rue des Bruyères, L-1274, HOWALD, Luxembourg (LU)
- To:
Publication
Bulletin
- Bulletin Heading:
- SPC1
- Bulletin edition number:
- 2023/01
- Publication date:
- 03/01/2023
- Description:
- Section C : Published requests for Supplementary Protection Certificates – I1 publication
Annual Fees
- Annual Fee Due Date:
- 31/05/2033
- Annual Fee Number:
- 21
- Annual Fee Amount:
- 410 Euro
- Expected Payer:
- Last Annual Fee Payment Date:
- Last Annual Fee Paid Number:
- Payer:
| Filing date | Document type | Number of pages |
|---|---|---|
| 02/12/2022 | Application Form | 6 |
| 02/12/2022 | Marketing authorization | 3 |
| 02/12/2022 | MA publication | 8 |
| 02/12/2022 | General Document | 4 |
| 02/12/2022 | Summary of the product caracteristics | 35 |
| 05/12/2022 | Outgoing Correspondence | 1 |
| 05/12/2022 | Publication | 1 |